Shenzhou Tai Yue Software and other seven companies pre-disclosure gem Prospectus

Our reporter Elaphe gem launched the footsteps of the increasingly approaching, 7 applications for the initial public offering of shares and listed in the Gem September 13 on the China Securities Regulatory Commission website in advance Disclosure Gem IPO Prospectus (report).　　Seven companies issued by the Internet to share the allocation of objects to the distribution of the distribution of funds and online purchase pricing method of the combination. Beijing Li-Chen Technology Co., Ltd. is proposed to issue 26.5 million shares, accounting for the total share capital after the issuance of 25.2%, the State Sea securities for the issue of sponsors.　　Raise funds mainly to the service and marketing network construction and Research and Development center project, total investment 27,622.760,000 Yuan. As an office information system service provider, Li-Chen technology mainly for government agencies and large and medium-sized enterprises and institutions, for the office and business processes in all types of information flow and processing, management-oriented outsourcing services as the core, to provide office information System solutions and services. The company ranks first in the service industry of office information system in China.　　2006-2008, the company's net profit composite growth rate of 71.22%, the first half of this year attributable to the parent company's shareholders net profit of 18.85 million yuan.　　Beijing Shenzhou Yue Software Co., Ltd. this time the proposed issue of 31.6 million shares, accounting for the total share capital after the issuance of 25%, Citic Securities for the issue of sponsors. Shenzhou Thai Yue Since its inception has been focused on the development of IT Operations management field, the main business for the domestic telecommunications, finance, energy and other industries of large and medium-sized enterprises and government departments to provide IT operations and management of the overall solution, including software product development and sales, technical services and the corresponding system integration. The net profit attributable to the parent company's shareholders in the first half of this year is 117 million yuan.　　The distribution of funds will be mainly invested in six projects, including a large-scale upgrading of the flying letter platform, totaling about 50,252 800,000 yuan.　　Le PU (Beijing) Medical Instrument Co., Ltd. is to issue 41 million shares, accounting for the total share capital after the issuance of 10.1%, Xinda Securities for the issue of sponsors. Le PU medical treatment is mainly engaged in coronary artery interventional Medical Device research and development, production and sales, is the high-end medical devices in the field of domestic and foreign products to form a strong competition for a small number of enterprises. Our main products include intravascular drug (rapamycin)-eluting stent system, coronary stent delivery system. The net profit attributable to the parent company's shareholders in the first half of this year is 148 million yuan. The controlling shareholder is the No. 725 Institute of China Shipbuilding Heavy Industry Corporation.　　The company will mainly invest in 4 projects, including cardiovascular medicine stent and transmission line technical renovation construction project, total investment of about 516.73 million yuan.　　Qingdao Rui Tak Electric Co., Ltd. the proposed release of not more than 35 million shares, not more than 25.93% of the total share capital after issuance, GF Securities for the issue of sponsors. The company's main business is 220kV and the following variable distribution equipment design, manufacture and related technical services, main products for outdoor box-type substation, outdoor box-type switch station and indoor switchgear, mainly for railways, electricity, coalCarbon and other industries to provide users with highly reliable professional transformer substation equipment and related technical services. The net profit attributable to the parent company's shareholders in the first half of this year is 38.86 million yuan.　　The fund-raising will be mainly to the outdoor box-type power Equipment technical transformation projects, including four projects as well as supplementary liquidity, the total input to raise funds of about 400 million yuan.　　Shanghai Jia Hao ship Engineering Design Co., Ltd. is to issue 12.6 million shares, accounting for the total share capital after the issuance of 25%, Yuan securities for the issue of sponsors. Jia Hao ship to ship and marine engineering equipment design for the main business, is currently three of the largest and most powerful professional civil ship and marine engineering design Enterprises, the first half of this year attributable to the parent company's shareholders net profit of 21.45 million yuan.　　The company's fund-raising will be mainly to the ship Design Center and Marine Engineering Design Center project, the project is expected to total investment of 143.81 million yuan, the plan to use 120.56 million yuan to raise funds.　　Southern Wind Turbine Co., Ltd. to be issued no more than 24 million shares, security securities for the issue of sponsors. The company is the largest in southern China specializing in ventilation and air treatment system design and product development, manufacturing and sales of enterprises, the main business for nuclear power, subways, tunnels, wind turbine blades and large-scale industrial and civil construction of the five major areas. In the last three years, net profit annual growth rate averaged 163.51%, and the net profit for the first half of this year was 15.03 million yuan.　　The distribution of funds will be mainly to the nuclear power HVAC (HVAC) system core/non-nuclear grade equipment, such as localization of four projects, a total of 287.5 million yuan.　　Chongqing Lai Mei Pharmaceutical Co., Ltd. the number of this issue is not less than 25% of the total shares issued after the issuance, and not more than 23 million shares, the National Gold securities for the issue of sponsors. The company is based on research and development, production and marketing of new drugs technology-based Pharmaceutical enterprises, the main products cover anti-infective and characteristics of the two series of specialized drugs, the main products have quinolones anti-infective drugs, anti-tumor drugs, parenteral nutrition drugs. The net profit attributable to the parent company's shareholders in the first half of this year is 17.98 million yuan. Raise funds will be mainly to the anti-infection and special specialty medicine industrialization production Base construction project, the total investment is 14,422.300,000 Yuan.